e-learning
resources
Milan 2017
Monday, 11.09.2017
Human susceptibility to tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of low-dose aspirin in a murine model of active tuberculosis
V. Kroesen (Bramsche, Germany)
Source:
International Congress 2017 – Human susceptibility to tuberculosis
Session:
Human susceptibility to tuberculosis
Session type:
Poster Discussion
Number:
3042
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Kroesen (Bramsche, Germany). Effect of low-dose aspirin in a murine model of active tuberculosis. 3042
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
The effect of combined therapy using rosuvastatin and dihydroarteminin in a pulmonary malaria mouse model.
Source: International Congress 2018 – Role of microbial exposure and inflammation in lung injury
Year: 2018
Effect of clarithromycin alone and clarithromycin containing regimen for
mycobacteriun avium
complex pulmonary disease
Source: Eur Respir J 2006; 28: Suppl. 50, 558s
Year: 2006
Switch effects from daily to intermittent treatment with a daily regimen dosage for Mycobacterium avium complex pulmonary disease
Source: International Congress 2019 – Clinical and translational studies of bronchiectasis and non-TB mycobacterial infection
Year: 2019
Comparative study of therapeutic effects of combination chemotherapy including various doses of clarithromycin for pulmonary
Mycobacterium avium
complex disease
Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis
Year: 2010
Effect of isoniazid prophylaxis for latent TB on interferon-gamma response
Source: Annual Congress 2007 - Gamma-interferon-based tests to diagnose tuberculosis infection and disease
Year: 2007
Effect of ICS/LABA combination in an ex vivo model of COPD exacerbation
Source: Virtual Congress 2020 – Clinical and basic pharmacology for COPD
Year: 2020
Comparison of efficacy and safety of fixed-dose combination regimen versus separate drugs for treatment of tuberculosis
Source: International Congress 2019 – Insights into paediatric bronchology
Year: 2019
Prevalence, screening and treatment of latent tuberculosis among oral corticosteroid recipients
Source: Eur Respir J 2014; 44: 1373-1375
Year: 2014
Effects of complex treatment with izofon of a pulmonary tuberculosis in children
Source: Eur Respir J 2004; 24: Suppl. 48, 652s
Year: 2004
Effect of Nintedanib in a rat model of lung fibrosis induced by single or double bleomycin administration
Source: International Congress 2017 – The wide spectrum of ILDs
Year: 2017
Treatment of severe Mycobacterium avium complex pulmonary disease with a adjunctive amikacin and clofazimine versus standard regimen alone, a retrospective study
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection I
Year: 2019
Effect on treatment of giving information about tuberculosis to the tuberculosis patients
Source: Eur Respir J 2005; 26: Suppl. 49, 644s
Year: 2005
Efficacy and safety of levamisole as an immunomodulator in the treatment of drug resistant tuberculosis
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II
Year: 2019
Airway administration of therapeutic antibody (tAb) confers higher protection than parenteral administration in a murine model of acute lung infection
Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies
Year: 2018
Effect of additional drug resistance of M tuberculosis in patients with Hr-TB on the efficacy of chemotherapy
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II
Year: 2019
Treatment outcome of combination antibiotic therapy including clarithromycin for
Mycobacterium avium
complex pulmonary disease
Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis
Year: 2010
Effect of azithromycin treatment on inflammation in COPD patients
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
The effect of HIV-associated tuberculosis, tuberculosis-IRIS and prednisone on lung function
Source: Eur Respir J, 55 (3) 1901692; 10.1183/13993003.01692-2019
Year: 2020
Effect of genotype on hypersensitivity pneumonitis despite treatment.
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Year: 2018
Long-term results of drug resistant tuberculosis treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 378s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept